EFFICIENCY OF AFLIBERCEPT IN CLINICAL PRACTICE

EFFICIENCY OF AFLIBERCEPT IN CLINICAL PRACTICE

Introduction. Age-related macular degeneration is a leading cause of severe vision loss worldwide, frequently resulting in legal blindness. Implementation of anti-VEGF therapy in clinical practice was an important milestone in the treatment of age-related macular degeneration. Despite various diseas...

Full description

Bibliographic Details
Main Author:	A. V. Kulagina
Format:	Article
Language:	Russian
Published:	Publishing house "Ophthalmology" 2017-09-01
Series:	Офтальмохирургия
Subjects:	wet amd rpe detachment neovascularization anti-vegf therapy aflibercept
Online Access:	https://www.ophthalmosurgery.ru/jour/article/view/338

Similar Items

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
by: Koike N, et al.
Published: (2019-07-01)

Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration
by: Pelin Kıyat, et al.
Published: (2021-06-01)

Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study
by: Korol AR, et al.
Published: (2017-07-01)

Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding
by: Julia de Lima Farah, et al.
Published: (2018-10-01)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
by: Praveen Yerramothu
Published: (2018-07-01)

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
by: Agnieszka Nowosielska
Published: (2019-10-01)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
by: Mohamed A. Hamid, et al.
Published: (2021-04-01)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
by: Garweg JG
Published: (2019-07-01)

Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration
by: Avaylon J, et al.
Published: (2020-05-01)

Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
by: Aditya Bansal, et al.
Published: (2017-01-01)

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
by: Pallavi Tyagi, et al.
Published: (2018-06-01)

Treatment of corneal neovascularization with topical aflibercept in a case of exposure keratopathy following cerebellar astrocytoma surgery
by: Sibel Aksoy
Published: (2019-01-01)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
by: Christof Haensli, et al.
Published: (2021-06-01)

Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
by: Kendra A. Klein, et al.
Published: (2017-04-01)

Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study
by: Paolo Corazza, et al.
Published: (2021-08-01)

Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration
by: Joel Hanhart, et al.
Published: (2017-10-01)

Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity
by: Vasumathy Vedantham
Published: (2019-01-01)

Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization
by: Tariq Al-Debasi, et al.
Published: (2017-04-01)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
by: Tran THC, et al.
Published: (2021-05-01)

Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia
by: Polona Jaki Mekjavić, et al.
Published: (2018-12-01)

Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks
by: Ebru Esen, et al.
Published: (2015-01-01)

One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
by: Ali Salimi, et al.
Published: (2021-01-01)

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
by: Taipale C, et al.
Published: (2018-12-01)

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
by: Kei Muro, et al.
Published: (2020-03-01)

Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina
by: Carsten Balser, et al.
Published: (2019-02-01)

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
by: Flora Elwes, et al.
Published: (2018-01-01)

Efficacy of combined use of anti-VEGF (Aflibercept) and lasercoagulation for corneal neovascularisation before keratoplasty
by: V. R. Mamikonyan, et al.
Published: (2018-12-01)

No improvement in injection frequency or in visual outcome over time in two cohorts of patients from the same Swedish county treated for wet age-related macular degeneration
by: Schroeder M, et al.
Published: (2017-06-01)

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
by: Spooner K, et al.
Published: (2017-01-01)

Intravitreal aflibercept for choroidal neovascularization secondary to angioid streaks in a non-responder to intravitreal ranibizumab
by: Makri OE, et al.
Published: (2018-09-01)

Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration
by: Mohamed Kamel Soliman, et al.
Published: (2021-09-01)

Correlation of Baseline Visual Acuity with Outcomes of Treatment with Anti-VEGF in Neovascular Age-Related Macular Degeneration
by: Veluswamy B, et al.
Published: (2020-06-01)

Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study
by: Clement K. Chan, et al.
Published: (2020-12-01)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
by: Jia-Kang Wang, et al.
Published: (2018-09-01)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
by: Vasileios E. Konidaris, et al.
Published: (2018-10-01)

Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD: results of real life ELU study
by: Frederic Queguiner, et al.
Published: (2020-02-01)

Short-term efficacy of intravitreal Aflibercept injections for retinal angiomatous proliferation
by: Hung-Da Chou, et al.
Published: (2017-06-01)

Efficacy of aflibercept in patients with neovascular age-related macular degeneration when combined with cataract surgery
by: A. A. Kuznetsov, et al.
Published: (2018-10-01)

Comparison of the effectiveness of various protocols for the transition to aflibercept with tachyphylaxis for ranibizumab in patients with neovascular AMD
by: A. N. Kulikov, et al.
Published: (2018-11-01)

Pharmacological Analysis of Resistance to Anti-VEGF Therapy
by: M. V. Budzinskaya, et al.
Published: (2019-01-01)